DTIL
HEALTHCAREPrecision Biosciences Inc
$7.52+0.07 (+0.94%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DTIL Today?
No stock-specific AI insight has been generated for DTIL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.53$8.82
$7.52
Fundamentals
Market Cap$194M
P/E Ratio—
EPS$-2.17
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin-1.3%
Debt / Equity—
Trading
Volume332K
Avg Volume (10D)—
Shares Outstanding25.8M
DTIL News
20 articles- Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 5, 2026
- Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 5, 2026
- Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026Yahoo Finance·Apr 30, 2026
- Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD StudyYahoo Finance·Apr 29, 2026
- Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual MeetingYahoo Finance·Apr 28, 2026
- AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?Yahoo Finance·Apr 27, 2026
- Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 24, 2026
- Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026Yahoo Finance·Apr 22, 2026
- Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 20, 2026
- Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European CountriesYahoo Finance·Apr 15, 2026
- Should You Buy Precision BioSciences (DTIL) After Golden Cross?Yahoo Finance·Apr 14, 2026
- Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue EstimatesYahoo Finance·Mar 12, 2026
- Precision BioSciences: Q4 Earnings SnapshotYahoo Finance·Mar 12, 2026
- Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 12, 2026
- Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV ProgramYahoo Finance·Mar 11, 2026
- Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026Yahoo Finance·Mar 10, 2026
- Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 9, 2026
- Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026Yahoo Finance·Mar 9, 2026
- Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor EventYahoo Finance·Mar 9, 2026
All 20 articles loaded
Price Data
Open$7.07
Previous Close$7.45
Day High$7.53
Day Low$6.50
52 Week High$8.82
52 Week Low$3.53
52-Week Range
$3.53$8.82
$7.52
Fundamentals
Market Cap$194M
P/E Ratio—
EPS$-2.17
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin-1.3%
Debt / Equity—
Trading
Volume332K
Avg Volume (10D)—
Shares Outstanding25.8M
About Precision Biosciences Inc
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—